Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities (NYSE:TEVA)

Johnce/E+ via Getty Images Teva’s Prescription for Profit: Simlandi’s Market Shake-Up Since my December call for a “revival” in Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) stock for the new year, shares are up 32%, beating the market’s performance (SPY) of 11% in the same time period. Seeking Alpha Over the weekend, Teva made a regulatory announcement…

Read More

Alvotech: FDA Overhang Remains, Remaining Constructive, Initiate Hold (NASDAQ:ALVO)

Matteo Colombo Investment briefing The biosimilars drug market is forecast to expand at a geometric growth rate of ~18% from 2023—2028, garnishing immense capital inflows along the way. Alvotech (NASDAQ:ALVO) is firmly positioned within the biosimilars value chain and has the potential to unlock compelling value should it successfully convert its pipeline assets. To date,…

Read More